Synthesis of Benzocycloalkanone-Based Michael Acceptors and Biological Activities as Antimalarial and Antitrypanosomal Agents.

A series of benzocycloalkanone derivatives have been prepared and evaluated as antimalarial and antitrypanosomal agents. The compounds were obtained by direct coupling of preformed 4-substituted benzaldehyde and indanone or tetralone substitutes through aldol condensation of Claisen-Schmidt using sodium hydroxide as a catalyst in ethanol at room temperature. Although designed to inhibit the formation of ß-hematin in vitro, only three compounds, 10, 11, and 12, showed activities greater than 50% (75.16%, 63.02%, and 56.17%, respectively). The results of the in vivo antimalarial evaluation show that 10, 11, and 12 reduced parasitemia marginally, and an insignificant increase in the days of survival of the mice was observed. As trypanocidals, all compounds showed marginal activity as inhibitors of the proliferation of T. cruzi epimastigotes, except compound 33, with an activity of 51.08 ± 3.4% compared to the activity shown by the reference compound benznidazole 59.99 ± 2.9%. The compounds appear to have little cytotoxic effect against VERO cells in vitro; this new class of Michael acceptor agents clearly warrants further investigation.

Molecular Mechanisms of Chloroquine and Hydroxychloroquine Used in Cancer Therapy.

Tumour relapse, chemotherapy resistance, and metastasis continue to be unsolved issues in cancer therapy. A recent approach has been to scrutinise drugs used in the clinic for other illnesses and modify their structure to increase selectivity to cancer cells. Chloroquine (CQ) and hydroxychloroquine (HCQ), known antimalarials, have successfully treated autoimmune and neoplastic diseases. CQ and HCQ, well-known lysosomotropic agents, induce apoptosis, downregulate autophagy, and modify the tumour microenvironment. Moreover, they affect the Toll 9/NF-κB receptor pathway, activate stress response pathways, enhance p53 activity and CXCR4-CXCL12 expression in cancer cells, which would help explain their effects in cancer treatment. These compounds can normalise the tumourassociated vasculature, promote the activation of the immune system, change the phenotype of tumour-associated macrophages (from M2 to M1), and stimulate cancer-associated fibroblasts. We aim to review the historical aspects of CQ and its derivatives and the most relevant mechanisms that support the therapeutic use of CQ and HCQ for the treatment of cancer.

Anti-inflammatory activity of Croton cuneatus aqueous extract.

The aqueous extract of Croton cuneatus Klotz. (Euphorbiaceae), was tested for its antinociceptive effects using chemical and thermal test models in mice. Anti-inflammatory activity was determined in Sprague-Dawley rats in a model of acute plantar inflammation induced by bovine serum albumin. Croton cuneatus aqueous extract at doses of 7 mg/kg showed a significant anti-inflammatory effect compared with commonly used non-stereoidal drugs as ketoprofen, sodium diclofenac and ASA (acetylsalicylic acid).

Three new glutarimide alkaloids from Croton cuneatus.

Analysis of the dichloromethane extract of the aerial parts of Croton cuneatus led to the isolation of the new glutarimide alkaloids: julocrotol (1), isojulocrotol (2), and julocrotone (3) along with the known compounds julocrotonine (4), lichexanthone (5) and selin-11-en-4alpha-ol (6). The structures of the new compounds were established by spectral methods. The in vitro cytotoxic activity of Compounds 1-6 was evaluated against six human tumor cells lines.